Bemarituzumab
Based on 1 Customer Validation
Bemarituzumab (AMG 552) is a humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has antitumor activity against gastric and breast cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.82%
- CAS No.: 1952272-74-0
- Masse moléculaire:143.86 kDa
-
Stockage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-P99384
VofatamabAnti-FGFR3 mAb -
HY-P99007
AprutumabFGFR2-specific Monoclonal Antibody -
HY-100818
FutibatinibFGFR Inhibitor -
HY-P99058
ZolbetuximabClaudin-18.2 Inhibitor -
HY-P9907
TrastuzumabHER2 Blocking Antibody -
HY-13311
InfigratinibFGFR Inhibitor -
HY-P9905
CetuximabEGFR Inhibitor -
HY-10197
WortmanninPI3K Inhibitor -
HY-P99045
SacituzumabAnti-TROP-2 Antibody -
HY-18708
ErdafitinibFGFR Inhibitor -
HY-17371
OxaliplatinDNA Synthesis Inhibitor -
HY-138298
Trastuzumab deruxtecan (solution)HER2 ADC
Activité biologique
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
FGFR2/CD332
In Vitro
Bemarituzumab (0.001-100 μg/mL, 30 min) inhibits FGF7-induced FGFR2 phosphorylation and cell proliferation in a concentration-dependent manner in the SNU-16 human gastric cancer cells, reaching a maximal value at ≥6.25 μg/mL[2].
Bemarituzumab exhibits immune cell-mediated killing of tumor cells overexpressing FGFR2b[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Bemarituzumab (5 mg/kg; i.p.; twice a week) combined with 5-fluorouracil (HY-90006) and Oxaliplatin (HY-17371) significantly inhibits tumor growth more than monotherapy and does not increase chemotherapy-related toxicity in the OCUM-2M gastric cancer xenograft model[2].
Bemarituzumab (10 mg/kg; i.p.; biweekly) significantly reduces tumor burden, recruits NK cells, and increases PD-L1-expressing cells and CD3-positive T cells in the syngeneic 4T1 mouse mammary tumor model[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female CB17 SCID mice (7-8 weeks old), xenograft model of OCUM-2M human gastric cancer cells[2]
-
Dosage:1 mg/kg, 1.5 mg/kg, 2 mg/kg, 3 mg/kg, 5 mg/kg (in PBS)
-
Administration:Intravenous injection, twice a week
-
Result:Inhibited tumor growth in a dose-dependent manner.
Inhibited and regressed tumor growth starting from a dose of 1 mg/kg.
Caused complete tumor regression in 1/15 mice at the 1.5 mg/kg and 2 mg/kg doses, 4/15 mice at the 3 mg/kg dose, and 6/15 mice at the 5 mg/kg dose by day 42.
-
Animal Model:Tg-ArcSwe transgenic mice (11-14 months old) harboring the APP Arctic mutation[3]
-
Dosage:10 mg/kg
-
Administration:i.p., once weekly, for 4/13 weeks
-
Result:Achieved brain amyloid-β (Aβ) protofibril and cerebrospinal fluid (CSF) Aβ protofibrils/oligomers reduction.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized FGFR-2 alpha (IIIb) Protein, Human (HEK293, His, HY-P76336) can bind Bemarituzumab. The EC50 for this effect is 5.673 ng/mL.
Chemical Information
-
CAS No. 1952272-74-0
-
Appearance Liquid
-
Masse moléculaire 143.86 kDa
-
Color Colorless to light yellow
-
SMILES
[Bemarituzumab]
-
Synonyms
AMG 552; FPA-144
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Daniel Vt Catenacci, et al. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Future Oncol. 2019 Jun;15(18):2073-2082. [Content Brief]
[2]. Xiang H, et al. Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer. MAbs. 2021 Jan-Dec;13(1):1981202. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Bemarituzumab Related Classifications
HY-P99010 Related Classifications
Powered by Bioz